Drägerwerk stock at EUR 116.50, 7.10 percent below its yearly high

Published on 10/12/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk stock costs EUR 116.50 on October 12, 2026, 0.09 percent below the Xetra close. Market value is EUR 2.2 billion and P/E is 12.78.

Key points in brief

Drägerwerk stock was at EUR 116.50 at Lang & Schwarz on October 12, 2026, 0.09 percent below the October 9 Xetra close.
The price stood 7.10 percent below the EUR 125.40 52-week high and the market capitalization was EUR 2.2 billion.
The company guided for 2.0 to 6.0 percent currency-adjusted revenue growth and a 5.0 to 7.5 percent EBIT margin for fiscal 2026.
Siemens Healthineers traded up 0.54 percent and Getinge rose 0.36 percent in the comparison block.

Schwarzweiß-Reportagefoto eines Feuerwehrmanns mit Atemschutzgerät im Einsatz — Drägerwerk AG & Co. KGaA Sicherheitstechnik Feuerwehrmann Atemschutz dramatischer Einsatz Rauchgebäude DE0005550636, Illustration mit AI erstellt.

At Lang & Schwarz, Drägerwerk (ISIN DE0005550636) was trading at EUR 116.50 on October 12, 2026 at 1:47 p.m. CEST, 0.09 percent below the Xetra close of October 9, 2026 at EUR 116.60 and 7.10 percent below its 52-week high of EUR 125.40. The price places the medical and safety technology group below its yearly peak while keeping the latest market value at EUR 2.2 billion.

Range leaves 7.10 percent gap

The Lang & Schwarz quote showed a bid of EUR 116.20 and an ask of EUR 116.80 at the same timestamp. Trading volume was 1,707 shares as of October 12, 2026, compared with an average volume of 20,227 shares, a difference of 91.56 percent.

The 52-week range runs from EUR 59.90 to EUR 125.40. The current price is 94.49 percent above the low and 7.10 percent below the high, placing the stock in the upper part of its annual range.

Margins anchor the valuation

Drägerwerk had a market capitalization of EUR 2.2 billion, a price-to-earnings ratio of 12.78 and a dividend yield of 2.00 percent on October 12, 2026. These figures put the stock below the valuation multiples of the two medical technology peers used in the comparison below.

According to Dräger, fiscal 2026 guidance calls for currency-adjusted revenue growth of 2.0 to 6.0 percent and an EBIT margin of 5.0 to 7.5 percent. The company reported fiscal 2025 revenue growth of 5.3 percent and an EBIT margin of 6.7 percent, giving investors a concrete benchmark for the current outlook.

Comparison with peers

Drägerwerk: minus 0.09 percent, P/E 12.8, market capitalization EUR 2.2 billion
Siemens Healthineers (Xetra, EUR): plus 0.54 percent, P/E 19.9, market capitalization EUR 44.0 billion
Getinge (Nasdaq Stockholm, SEK): plus 0.36 percent, P/E 25.9, market capitalization SEK 69.2 billion

October 29 is the next date

According to Research Hub, mwb research raised its Drägerwerk price target from EUR 114.00 to EUR 130.00 in a report dated August 31, 2026. The target lies 11.59 percent above the Lang & Schwarz price, while the same research page lists the third-quarter results for October 29, 2026 and a capital markets day for November 18, 2026.

Price stays below the yearly high

Drägerwerk was trading at EUR 116.50 at Lang & Schwarz on October 12, 2026 at 1:47 p.m. CEST, 0.09 percent below the Xetra close of October 9, 2026 at EUR 116.60. The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.